99 related articles for article (PubMed ID: 17875735)
21. HIP1: trafficking roles and regulation of tumorigenesis.
Hyun TS; Ross TS
Trends Mol Med; 2004 Apr; 10(4):194-9. PubMed ID: 15059611
[TBL] [Abstract][Full Text] [Related]
22. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB.
Garrison JB; Samuel T; Reed JC
Oncogene; 2009 Apr; 28(13):1584-93. PubMed ID: 19234489
[TBL] [Abstract][Full Text] [Related]
23. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
24. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
25. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia.
Xu Y; Sumter TF; Bhattacharya R; Tesfaye A; Fuchs EJ; Wood LJ; Huso DL; Resar LM
Cancer Res; 2004 May; 64(10):3371-5. PubMed ID: 15150086
[TBL] [Abstract][Full Text] [Related]
26. [Leukemia in delta-GAG-MYC transgenic mice].
Shvemberger IN; Ginkul LB; Ermilov AN
Vopr Onkol; 1994; 40(4-6):198-202. PubMed ID: 7785244
[TBL] [Abstract][Full Text] [Related]
27. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development.
Kamimura K; Ohi H; Kubota T; Okazuka K; Yoshikai Y; Wakabayashi Y; Aoyagi Y; Mishima Y; Kominami R
Biochem Biophys Res Commun; 2007 Apr; 355(2):538-42. PubMed ID: 17306224
[TBL] [Abstract][Full Text] [Related]
28. Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues.
Graves CW; Philips ST; Bradley SV; Oravecz-Wilson KI; Li L; Gauvin A; Ross TS
Cancer Res; 2008 Feb; 68(4):1064-73. PubMed ID: 18281481
[TBL] [Abstract][Full Text] [Related]
29. Continuous cell culture from a highly undifferentiated mouse lymphoid neoplasm.
Hill M; Dvorák K; Spurná V
J Natl Cancer Inst; 1970 Feb; 44(2):307-17. PubMed ID: 11515072
[No Abstract] [Full Text] [Related]
30. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1.
Bradley SV; Hyun TS; Oravecz-Wilson KI; Li L; Waldorff EI; Ermilov AN; Goldstein SA; Zhang CX; Drubin DG; Varela K; Parlow A; Dlugosz AA; Ross TS
Hum Mol Genet; 2007 Jun; 16(11):1279-92. PubMed ID: 17452370
[TBL] [Abstract][Full Text] [Related]
31. Actin binding by Hip1 (huntingtin-interacting protein 1) and Hip1R (Hip1-related protein) is regulated by clathrin light chain.
Wilbur JD; Chen CY; Manalo V; Hwang PK; Fletterick RJ; Brodsky FM
J Biol Chem; 2008 Nov; 283(47):32870-9. PubMed ID: 18790740
[TBL] [Abstract][Full Text] [Related]
32. Acetylation and oxidation phenotypes in malignant lymphoma.
Philip PA; Rogers HJ; Harper PG
Cancer Chemother Pharmacol; 1987; 20(3):235-8. PubMed ID: 3677298
[TBL] [Abstract][Full Text] [Related]
33. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.
Rao DS; Bradley SV; Kumar PD; Hyun TS; Saint-Dic D; Oravecz-Wilson K; Kleer CG; Ross TS
Cancer Cell; 2003 May; 3(5):471-82. PubMed ID: 12781365
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure at 2.8 A of the DLLRKN-containing coiled-coil domain of huntingtin-interacting protein 1 (HIP1) reveals a surface suitable for clathrin light chain binding.
Ybe JA; Mishra S; Helms S; Nix J
J Mol Biol; 2007 Mar; 367(1):8-15. PubMed ID: 17257618
[TBL] [Abstract][Full Text] [Related]
35. Molecular diagnosis in lymphoma.
Bagg A
Curr Hematol Rep; 2005 Jul; 4(4):313-23. PubMed ID: 16009047
[TBL] [Abstract][Full Text] [Related]
36. Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.
Kreher S; Bouhlel MA; Cauchy P; Lamprecht B; Li S; Grau M; Hummel F; Köchert K; Anagnostopoulos I; Jöhrens K; Hummel M; Hiscott J; Wenzel SS; Lenz P; Schneider M; Küppers R; Scheidereit C; Giefing M; Siebert R; Rajewsky K; Lenz G; Cockerill PN; Janz M; Dörken B; Bonifer C; Mathas S
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4513-22. PubMed ID: 25288773
[TBL] [Abstract][Full Text] [Related]
37. Hip1-related mutant mice grow and develop normally but have accelerated spinal abnormalities and dwarfism in the absence of HIP1.
Hyun TS; Li L; Oravecz-Wilson KI; Bradley SV; Provot MM; Munaco AJ; Mizukami IF; Sun H; Ross TS
Mol Cell Biol; 2004 May; 24(10):4329-40. PubMed ID: 15121852
[TBL] [Abstract][Full Text] [Related]
38. [Chromatographic study of phospholipids in the lymph nodes in some lympho-proliferative diseases].
Mihăilescu E; Olinescu V; Micu D
Stud Cercet Med Interna; 1971; 12(3):245-9. PubMed ID: 5171677
[No Abstract] [Full Text] [Related]
39. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies.
Ek S; Andréasson U; Hober S; Kampf C; Pontén F; Uhlén M; Merz H; Borrebaeck CA
Mol Cell Proteomics; 2006 Jun; 5(6):1072-81. PubMed ID: 16524965
[TBL] [Abstract][Full Text] [Related]
40. An integrated computational/experimental model of lymphoma growth.
Frieboes HB; Smith BR; Chuang YL; Ito K; Roettgers AM; Gambhir SS; Cristini V
PLoS Comput Biol; 2013; 9(3):e1003008. PubMed ID: 23555235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
